Abstract
Background and aims: Epidemiological studies have examined the association between the use of non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of Alzheimer's disease (AD). Recently, a variety of experimental studies indicates that a subset of NSAIDs, such as ibuprofen or flurbiprofen, also have Aβ-lowering properties in both AD transgenic mice and cell cultures of peripheral, glial and neuronal origin. In this trial, we evaluated whether the non-selective NSAID ibuprofen slows disease progression in patients with mild to moderate AD. Methods: This was a 12-month multicenter, randomized, double-blind, placebo-controlled, parallel group trial. Participants with mild-moderate AD (Mini-Mental State Examination score >15, 0.20). In intention-to-treat analysis, ADAS-Cog score worsening was similar in the two groups (p=0.951, treatment difference= 0.1, CI -2.7; 2.9). No differences were found for any secondary outcomes. In a subsample of genotyped patients, ApoE ε4 carriers treated with ibuprofen (n=27) were the only group without significant cognitive decline. Conclusions: Ibuprofen, if used for relatively short periods of time and although well tolerated thanks to gastroprotection, does not seem to be effective in tertiary prevention of mild-moderate AD. Our results suggest the need to examine whether differences in the response to NSAIDs exist, based on ApoE ε4 carrier status.
| Original language | English |
|---|---|
| Pages (from-to) | 102-110 |
| Number of pages | 9 |
| Journal | Aging clinical and experimental research |
| Volume | 21 |
| Issue number | 2 |
| Publication status | Published - Apr 2009 |
Fingerprint
Keywords
- Alzheimer disease
- ApoE ε4 carriers
- Cognitive decline
- Ibuprofen
ASJC Scopus subject areas
- Ageing
- Geriatrics and Gerontology
Cite this
A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease. / Pasqualetti, Patrizio; Bonomini, Cristina; Dal Forno, Gloria; Paulon, Luca; Sinforiani, Elena; Marra, Camillo; Zanetti, Orazio; Rossini, Paolo Maria.
In: Aging clinical and experimental research, Vol. 21, No. 2, 04.2009, p. 102-110.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease
AU - Pasqualetti, Patrizio
AU - Bonomini, Cristina
AU - Dal Forno, Gloria
AU - Paulon, Luca
AU - Sinforiani, Elena
AU - Marra, Camillo
AU - Zanetti, Orazio
AU - Rossini, Paolo Maria
PY - 2009/4
Y1 - 2009/4
N2 - Background and aims: Epidemiological studies have examined the association between the use of non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of Alzheimer's disease (AD). Recently, a variety of experimental studies indicates that a subset of NSAIDs, such as ibuprofen or flurbiprofen, also have Aβ-lowering properties in both AD transgenic mice and cell cultures of peripheral, glial and neuronal origin. In this trial, we evaluated whether the non-selective NSAID ibuprofen slows disease progression in patients with mild to moderate AD. Methods: This was a 12-month multicenter, randomized, double-blind, placebo-controlled, parallel group trial. Participants with mild-moderate AD (Mini-Mental State Examination score >15, 0.20). In intention-to-treat analysis, ADAS-Cog score worsening was similar in the two groups (p=0.951, treatment difference= 0.1, CI -2.7; 2.9). No differences were found for any secondary outcomes. In a subsample of genotyped patients, ApoE ε4 carriers treated with ibuprofen (n=27) were the only group without significant cognitive decline. Conclusions: Ibuprofen, if used for relatively short periods of time and although well tolerated thanks to gastroprotection, does not seem to be effective in tertiary prevention of mild-moderate AD. Our results suggest the need to examine whether differences in the response to NSAIDs exist, based on ApoE ε4 carrier status.
AB - Background and aims: Epidemiological studies have examined the association between the use of non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of Alzheimer's disease (AD). Recently, a variety of experimental studies indicates that a subset of NSAIDs, such as ibuprofen or flurbiprofen, also have Aβ-lowering properties in both AD transgenic mice and cell cultures of peripheral, glial and neuronal origin. In this trial, we evaluated whether the non-selective NSAID ibuprofen slows disease progression in patients with mild to moderate AD. Methods: This was a 12-month multicenter, randomized, double-blind, placebo-controlled, parallel group trial. Participants with mild-moderate AD (Mini-Mental State Examination score >15, 0.20). In intention-to-treat analysis, ADAS-Cog score worsening was similar in the two groups (p=0.951, treatment difference= 0.1, CI -2.7; 2.9). No differences were found for any secondary outcomes. In a subsample of genotyped patients, ApoE ε4 carriers treated with ibuprofen (n=27) were the only group without significant cognitive decline. Conclusions: Ibuprofen, if used for relatively short periods of time and although well tolerated thanks to gastroprotection, does not seem to be effective in tertiary prevention of mild-moderate AD. Our results suggest the need to examine whether differences in the response to NSAIDs exist, based on ApoE ε4 carrier status.
KW - Alzheimer disease
KW - ApoE ε4 carriers
KW - Cognitive decline
KW - Ibuprofen
UR - http://www.scopus.com/inward/record.url?scp=66849143701&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=66849143701&partnerID=8YFLogxK
M3 - Article
VL - 21
SP - 102
EP - 110
JO - Aging clinical and experimental research
JF - Aging clinical and experimental research
SN - 1594-0667
IS - 2
ER -